









Markets
/
Stocks
/
nasdaq-neo
/

Neogenomics Inc

NEO

8.620USD

+0.510+6.29%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.11BMarket Cap

LossP/E TTM



Neogenomics Inc

8.620

+0.510+6.29%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

29 / 72

Overall Ranking

167 / 4723

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Hold

Current Rating

9.591

Target Price

+20.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 29.59% year-on-year.

Overvalued

The company’s latest PE is -9.94, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 126.82M shares, decreasing 9.26% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 14.10M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.40, which is lower than the Healthcare Providers & Services industry's average of 7.42. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 181.33M, representing a year-over-year increase of 10.23%, while its net profit experienced a year-over-year increase of 141.88%.

Score

Industry at a Glance

Previous score

7.40

Change



Financials

7.71

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.11

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.62

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.36

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.19

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Providers & Services industry's average of 2.35. Its current P/E ratio is -9.94, which is 45.92% below the recent high of -14.51 and -121.85% above the recent low of -22.05.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 29/72

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 6.93, which is lower than the Healthcare Providers & Services industry's average of 7.58. The average price target for Neogenomics Inc is 11.00, with a high of 14.00 and a low of 3.50.

Score

Industry at a Glance

Previous score

6.93

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Hold

Current Rating

9.591

Target Price

+18.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Neogenomics Inc

NEO

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Natera Inc

NTRA

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 8.85, which is higher than the Healthcare Providers & Services industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 9.47 and the support level at 6.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.72

Change

0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.038

Buy

RSI(14)

65.054

Neutral

STOCH(KDJ)(9,3,3)

77.162

Buy

ATR(14)

0.579

Low Volatility

CCI(14)

94.478

Neutral

Williams %R

25.882

Buy

TRIX(12,20)

1.108

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

8.152

Buy

MA10

8.035

Buy

MA20

7.721

Buy

MA50

6.788

Buy

MA100

7.159

Buy

MA200

10.081

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Providers & Services industry's average of 8.03. The latest institutional shareholding proportion is 98.17%, representing a quarter-over-quarter decrease of 3.88%. The largest institutional shareholder is The Vanguard, holding a total of 14.10M shares, representing 10.92% of shares outstanding, with 1.40% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

18.29M

-1.91%

The Vanguard Group, Inc.

Star Investors

14.23M

+0.12%

Greenhouse Funds LLLP

4.71M

+0.14%

First Light Asset Management, LLC

6.04M

+90.77%

State Street Global Advisors (US)

5.09M

-2.10%

Macquarie Investment Management

4.68M

+22.67%

Dimensional Fund Advisors, L.P.

3.85M

+11.88%

Schroder Investment Management North America Inc.

4.31M

+13.42%

American Century Investment Management, Inc.

3.32M

+14.74%

Millennium Management LLC

6.72M

+371.20%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.06, which is lower than the Healthcare Providers & Services industry's average of 4.17. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.